DA-1726

Asset

Oxyntomodulin analogue that activates GLP-1 and glucagon receptors to promote weight loss.

Stage
Phase 1
Modality
Peptide
Target
GLP1R
1
Indication
0
Trials
1
Developer

Indications

1
  • Obesity

    Phase 1, doi.org, 5 Jun 2026

In the full profile

  • Targets and what it contains2
  • Owner and partners2
  • Evidence for its targets3
  • Competitors12
  • Signals3

Every asset’s record: target, stage, trials and the evidence behind it.

See Pro

Assets